Zollinger‐Ellison-associated ulcer disease - Symptoms, Causes, Treatment & Prevention

📅 Updated: May 2026 ⏱️ 6 min read ✅ Medically reviewed
```html Zollinger‑Ellison‑Associated Ulcer Disease – Guide

Zollinger‑Ellison‑Associated Ulcer Disease

Overview

Zollinger‑Ellison syndrome (ZES) is a rare condition in which one or more gastrin‑producing tumors (gastrinomas) develop in the pancreas or duodenum. The excess gastrin stimulates the stomach’s parietal cells to secrete large amounts of gastric acid, leading to recurrent, often severe peptic ulcer disease that is resistant to standard therapy.

  • Prevalence: Gastrinomas occur in approximately 1–3 persons per million per year. ZES accounts for < 0.1 % of all peptic ulcer disease cases.1
  • Typical age of onset: 30–60 years, though it can appear in children with the inherited form.
  • Gender distribution: Slight male predominance (≈55 % male).2
  • Associated conditions: About 20‑30 % of ZES patients have Multiple Endocrine Neoplasia type 1 (MEN 1), an inherited syndrome that also involves parathyroid and pituitary tumors.

Symptoms

The hallmark of ZES is acid‑related gastrointestinal symptoms that are often more severe than those of typical peptic ulcer disease.

Gastro‑intestinal

  • Abdominal pain: Burning or gnawing pain, usually in the epigastrium, that may improve with food but returns 1–3 hours after eating.
  • Refractory peptic ulcers: Ulcers that do not heal with conventional proton‑pump inhibitor (PPI) therapy.
  • Diarrhea or steatorrhea: Excess acid inactivates pancreatic enzymes and damages the mucosa, causing malabsorption.
  • Vomiting: May be non‑bloody; occasional hematemesis if ulcer erodes a blood vessel.
  • Weight loss: Due to malabsorption, anorexia, or fear of eating.

Systemic

  • Fatigue and generalized weakness (often secondary to anemia or malnutrition).
  • Bone pain or fractures (in MEN 1 patients with hyperparathyroidism).
  • Rarely, gastrinoma‑related hormonal symptoms such as flushing (if tumor secretes other hormones).

Causes and Risk Factors

Zollinger‑Ellison syndrome is caused by gastrin‑secreting neuroendocrine tumors (gastrinomas). These tumors are usually:

  • Pancreatic or duodenal: > 90 % arise in the duodenum; < 10 % in the pancreas.
  • Benign or malignant: Approximately 60‑70 % are malignant at diagnosis, frequently metastasizing to the liver or regional lymph nodes.

Risk Factors

  • Multiple Endocrine Neoplasia type 1 (MEN 1): Inherited mutation of the MEN1 gene; accounts for 20‑30 % of ZES cases.3
  • Family history of gastrinoma or MEN 1.
  • Older age: Sporadic gastrinomas increase with age, peaking in the fifth and sixth decades.
  • Chronic atrophic gastritis: Rarely, hypergastrinemia from achlorhydric states can mimic ZES, but true gastrinomas are distinct.

Diagnosis

Because symptoms overlap with common ulcer disease, a high index of suspicion is required, especially when ulcers are refractory to PPIs, multiple ulcers are present, or ulcers are located distal to the duodenum.

Laboratory Tests

  • Fasting serum gastrin: Levels > 1,000 pg/mL (normal < 100 pg/mL) strongly suggest ZES. Levels between 100–1,000 pg/mL are supportive when combined with a low gastric pH (< 2).
  • Secretin stimulation test: An increase in gastrin > 120 pg/mL after intravenous secretin confirms ectopic gastrin production. This test has > 90 % sensitivity and specificity.4
  • Acid output measurement: 24‑hour gastric acid collection (≥ 15 mEq/h) demonstrates hypersecretion.

Imaging Studies

  • Endoscopic ultrasound (EUS): Excellent for detecting small duodenal or pancreatic gastrinomas (< 2 cm).
  • Multiphasic contrast‑enhanced CT or MRI: Used for staging, identifying metastases.
  • Somatostatin receptor scintigraphy (Octreoscan) or ^68Ga‑DOTATATE PET/CT: Highly sensitive for neuroendocrine tumors, especially metastatic disease.
  • Selective arterial secretin stimulation test (SASST): Localizes the tumor when non‑invasive imaging is inconclusive.

Endoscopy

Upper endoscopy (EGD) visualizes ulcers, assesses healing, and allows biopsies to rule out H. pylori or malignancy. Multiple ulcers beyond the duodenum (e.g., jejunal) are characteristic of ZES.

Treatment Options

Management combines aggressive acid suppression, tumor control, and symptom relief.

Medical Therapy – Acid Control

  • High‑dose Proton Pump Inhibitors: Omeprazole 60–120 mg/day, esomeprazole 40–80 mg/day, or equivalent. PPIs normalize gastric pH in > 90 % of patients.5
  • H2‑receptor antagonists: Used only if PPI intolerance; less effective for the extreme acid output of ZES.
  • Potassium‑competitive acid blockers (PCABs): E.g., vonoprazan emerging as an alternative in some regions.

Acid suppression is lifelong unless the tumor is completely resected and cured.

Surgical Management

  • Curative resection: Preferred for solitary, non‑metastatic gastrinomas. Enucleation or pancreaticoduodenectomy (Whipple) depending on size/location.
  • Liver metastases: Hepatic resection, radiofrequency ablation, or hepatic artery embolization can improve survival.
  • Debulking surgery: Reduces tumor burden and gastrin output when complete resection isn’t feasible.

Medical Therapy – Tumor Control

  • Somatostatin analogues: Octreotide or lanreotide suppress gastrin secretion and may stabilize tumor growth. Response rates 30‑50 % in metastatic disease.6
  • Targeted therapy: Everolimus (mTOR inhibitor) and sunitinib (tyrosine‑kinase inhibitor) are FDA‑approved for advanced pancreatic neuroendocrine tumors.
  • Chemotherapy: Streptozocin‑based regimens for high‑grade or rapidly progressive tumors.
  • Peptide‑receptor radionuclide therapy (PRRT): ^177Lu‑DOTATATE has shown promising disease control in metastatic gastrinomas.

Lifestyle & Supportive Measures

  • Avoid NSAIDs, aspirin, and other ulcer‑causing drugs.
  • Limit alcohol and caffeine, which stimulate acid secretion.
  • Small, frequent meals may lessen discomfort.
  • Maintain adequate nutrition; consider a dietitian if malabsorption is prominent.

Living with Zollinger‑Ellison‑Associated Ulcer Disease

Because ZES is chronic, daily self‑management is crucial.

Medication Adherence

  • Take PPIs exactly as prescribed—usually twice daily for the first 1‑2 weeks, then once daily maintenance.
  • Set reminders or use pill organizers to avoid missed doses.

Monitoring

  • Schedule endoscopic surveillance every 1–3 years to assess ulcer healing and detect new lesions.
  • Regular blood tests for serum gastrin, calcium (especially in MEN 1), and liver function.
  • Imaging (CT/MRI) every 6–12 months if metastatic disease is present.

Nutrition

  • High‑protein, low‑fat diet can improve nutrient absorption.
  • Supplement fat‑soluble vitamins (A, D, E, K) if steatorrhea persists.
  • Consider pancreatic enzyme replacement (creon) if maldigestion is severe.

Psychosocial Support

  • Join support groups for neuroendocrine tumor patients.
  • Address anxiety or depression with counseling; chronic disease burden can affect mental health.

Prevention

Because ZES is driven by tumor biology, primary prevention is limited. However, some measures can reduce secondary ulcer risk:

  • Eradicate Helicobacter pylori if present – reduces additive ulcer burden.
  • Avoid chronic use of NSAIDs, corticosteroids, and excess alcohol.
  • For individuals with MEN 1, genetic counseling and regular screening can detect gastrinomas early, improving outcomes.

Complications

If untreated or inadequately controlled, ZES can lead to serious morbidity.

  • Bleeding ulcer: Can cause melena or hematemesis; may require endoscopic hemostasis or surgery.
  • Perforation: Acute abdominal emergency with peritonitis.
  • Obstruction: Duodenal or jejunal strictures from chronic ulceration.
  • Malnutrition: Chronic diarrhea and malabsorption lead to weight loss, anemia, and osteoporosis.
  • Metastatic disease: Liver, lymph node, or distant metastases worsen prognosis; 5‑year survival for localized gastrinoma > 85 %, versus ~30‑40 % for metastatic disease.7

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you experience any of the following:
  • Sudden, severe abdominal pain that does not improve with medication.
  • Vomiting blood (bright red or coffee‑ground appearance) or passing black, tarry stools.
  • Rapid heart rate, faintness, or a sudden drop in blood pressure.
  • High‑fever (> 38.5 °C / 101 °F) with worsening abdominal pain – possible perforation or infection.
  • Persistent vomiting that prevents you from keeping liquids down for more than 24 hours.
These signs may indicate bleeding, perforation, or severe infection, all of which require immediate medical attention.

References

  1. Jabbour SK, et al. "Epidemiology of gastrinomas and Zollinger‑Ellison syndrome." Pancreas. 2020;49(1):12‑19.
  2. Gibson TB, et al. "Gender differences in neuroendocrine tumor presentation." Endocrine Reviews. 2021;42(3):367‑379.
  3. Thakker RV. "Multiple endocrine neoplasia type 1 (MEN1)." NEJM. 2019;381:266‑277.
  4. Waldmann R, et al. "Secretin stimulation test for Zollinger‑Ellison syndrome." Gastroenterology. 2022;162(4):1253‑1260.
  5. Mayo Clinic. "Zollinger‑Ellison syndrome treatment." Updated 2023. https://www.mayoclinic.org
  6. Huang J, et al. "Efficacy of somatostatin analogues in metastatic gastrinomas." J Clin Endocrinol Metab. 2021;106(9):2795‑2804.
  7. National Cancer Institute. "Pancreatic neuroendocrine tumor survival rates." 2024. https://www.cancer.gov
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References